Global Continuous Glucose Monitoring Devices Market is valued approximately USD 7480.19 million in 2021 and is anticipated to grow with a healthy growth rate of more than 4.5% over the forecast period 2022-2029. Continuous glucose monitoring (CGM) devices are medical devices that are used to monitor the glucose levels in a person’s body continuously and in real-time. These devices are typically used by people with diabetes to manage their blood sugar levels. The major driving factors for the Global Continuous Glucose Monitoring Devices Market are increasing incidence of diabetes and growing Geriatric Population. Moreover, rising technological advancement and rising initiatives by the key market players is creating lucrative growth opportunity for the market over the forecast period 2022-2029.

In addition to high blood pressure and high cholesterol, prominent risk factors for diabetes complications include smoking, obesity, inactivity, and being overweight. According to the International Diabetes Federation, there were approximately 536.6 million cases of diabetes worldwide in 2021; this number is projected to rise to 642.8 million by 2030 and 783.7 million by 2045. However, the high cost of Continuous Glucose Monitoring Devices stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Continuous Glucose Monitoring Devices Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the largest market for CGM devices due to the high prevalence of diabetes in this region. The US is the largest market in North America due to the high adoption rate of CGM devices and the presence of key players in the region. Asia-Pacific is the fastest-growing market for CGM devices due to the increasing prevalence of diabetes in this region. The major markets in Asia-Pacific are China, Japan, India, and South Korea.

Major market player included in this report are:
F. Hoffmann-La Roche Ltd.
Dexcom Inc.
Abbott Laboratories
Medtronic Inc.
Ypsomed AG
GlySens Incorporated
Ascensia Diabetes Care
Dexcom
Abbott
Senseonics

Recent Developments in the Market:
- In June 2022, The EVERSENSE E3 continuous glucose monitoring system has been given a CE mark for usage in the European Union, according to a statement from Ascensia Diabetes Care.
Global Continuous Glucose Monitoring Devices Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Component, Connectivity, End-use, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Component offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Component:
Sensors
Transmitters
Receivers
By Connectivity:
Bluetooth
4G
By End-use:
Hospitals
Home Care
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World